Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib in Treating Patients With Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed relapsed or untreated mantle cell lymphoma~  * No refractory disease defined as progression while on chemotherapy or within 1 month after completion of chemotherapy~* At least 1 bidimensionally measurable disease site\*~  * Lymph nodes at least 1.5 cm by 1.5 cm by spiral CT scan OR~ * Non-nodal lesions (e.g., skin lesion or nodules) at least 1 cm by 1 cm by MRI, CT scan, or physical exam NOTE: \*Bone lesions are not considered bidimensionally measurable disease~* No pre-existing ascites or pleural effusion~* No known CNS involvement by lymphoma~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* At least 12 weeks~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 75,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* AST or ALT no greater than 2.5 times ULN~Renal:~* Creatinine no greater than 1.5 times ULN~Cardiovascular~* LVEF at least 45% by echocardiogram or MUGA~Pulmonary~* No pre-existing shortness of breath greater than grade 1~Other:~* No uncontrolled bacterial, fungal, or viral infections~* No pre-existing edema greater than grade 1~* No pre-existing neuropathy greater than grade 1~* No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or carcinoma in situ of the cervix~* No other serious illness or medical condition that would preclude study compliance~* No geographical conditions that would preclude study compliance~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Chemotherapy~* Prior rituximab allowed~* No prior radioactive monoclonal antibody therapy~Chemotherapy:~* See Disease Characteristics~* No prior high-dose chemotherapy with stem cell transplantation~* No more than 2 prior systemic chemotherapy regimens~  * Same chemotherapy combination given for first-line and second-line therapy is considered 2 regimens~* No prior flavopiridol~* At least 6 weeks since prior chemotherapy~* No concurrent cytotoxic chemotherapy~Endocrine therapy:~* No concurrent corticosteroids~Radiotherapy:~* No prior radiotherapy to 25% or more of functioning bone marrow~* At least 4 weeks since prior radiotherapy (except low-dose nonmyelosuppressive radiotherapy) and recovered~* No concurrent radiotherapy to the sole site of measurable disease~Surgery:~* At least 2 weeks since prior major surgery~Other:~* No prior investigational therapy~* No other concurrent anticancer therapy~* No other concurrent investigational anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete